STEEGMANN, J.L., M. BACCARANI, M. BRECCIA, L.F. CASADO, V. GARCÍA-GUTIÉRREZ, A. HOCHHAUS, D.-W. KIM, T.D. KIM, H.J. KHOURY, P. Le COUTRE, Jiří MAYER, D. MILOJKOVIC, K. PORKKA, D. REA, G. ROSTI, S. SAUSSELE, R. HEHLMANN a R.E. CLARK. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. London: Nature Publishing Group, roč. 30, č. 8, s. 1648-1671. ISSN 0887-6924. doi:10.1038/leu.2016.104. 2016.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Autoři STEEGMANN, J.L. (724 Španělsko), M. BACCARANI (380 Itálie), M. BRECCIA (380 Itálie), L.F. CASADO (724 Španělsko), V. GARCÍA-GUTIÉRREZ (724 Španělsko), A. HOCHHAUS (276 Německo), D.-W. KIM (410 Korejská republika), T.D. KIM (276 Německo), H.J. KHOURY (840 Spojené státy), P. Le COUTRE (276 Německo), Jiří MAYER (203 Česká republika, garant, domácí), D. MILOJKOVIC (826 Velká Británie a Severní Irsko), K. PORKKA (246 Finsko), D. REA (250 Francie), G. ROSTI (380 Itálie), S. SAUSSELE (276 Německo), R. HEHLMANN (276 Německo) a R.E. CLARK (724 Španělsko).
Vydání Leukemia, London, Nature Publishing Group, 2016, 0887-6924.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 11.702
Kód RIV RIV/00216224:14110/16:00090141
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1038/leu.2016.104
UT WoS 000380826400004
Klíčová slova anglicky CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE-KINASE INHIBITOR; DIAGNOSED CHRONIC-PHASE; CHROMOSOME-POSITIVE LEUKEMIAS; IMATINIB MESYLATE THERAPY; PATIENTS RECEIVING IMATINIB; ACUTE-RENAL-FAILURE
Štítky EL OK, podil
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 24. 10. 2016 14:49.
Anotace
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable and manageable, but they are increasingly important as therapy is potentially lifelong and multiple TKIs are available. For this reason, the European LeukemiaNet panel for CML management recommendations presents an exhaustive and critical summary of AEs emerging during CML treatment, to assist their understanding, management and prevention. There are five major conclusions. First, the main purpose of CML treatment is the antileukemic effect. Suboptimal management of AEs must not compromise this first objective. Second, most patients will have AEs, usually early, mostly mild to moderate, and which will resolve spontaneously or are easily controlled by simple means. Third, reduction or interruption of treatment must only be done if optimal management of the AE cannot be accomplished in other ways, and frequent monitoring is needed to detect resolution of the AE as early as possible. Fourth, attention must be given to comorbidities and drug interactions, and to new events unrelated to TKIs that are inevitable during such a prolonged treatment. Fifth, some TKI-related AEs have emerged which were not predicted or detected in earlier studies, maybe because of suboptimal attention to or absence from the preclinical data. Overall, imatinib has demonstrated a good long-term safety profile, though recent findings suggest underestimation of symptom severity by physicians. Second and third generation TKIs have shown higher response rates, but have been associated with unexpected problems, some of which could be irreversible. We hope these recommendations will help to minimise adverse events, and we believe that an optimal management of them will be rewarded by better TKI compliance and thus better CML outcomes, together with better quality of life.
VytisknoutZobrazeno: 28. 3. 2024 16:34